SEARCH

SEARCH BY CITATION

References

  • 1
    Bosch F X, Ribes J. The epidemiology of primary liver cancer: global epidemiology. In: TaborE, ed. Viruses and Liver Cancer. Amsterdam: Elsevier Science, 2002; 116.
  • 2
    Beasley R P. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma: epidemiologic considerations. Hepatology 1982; 2: 21s6s.
  • 3
    Tandon B N, Tandon A. Epidemiological trends of viral hepatitis in Asia. In: RizzettoM, PurcellR H, GerinJ L, VermeG, eds. Viral Hepatitis and Liver Disease. Turin: Edizioni Minera Medica, 1997; 55961.
  • 4
    Kew M C. Progress towards the comprehensive control of hepatitis B in Africa: a view from South Africa. Gut 1996; 38 (suppl. 2): 316.
  • 5
    Chang M H, Chen D S, Hsu H C, Hsu H Y, Lee C Y. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer 1989; 64: 237780.
  • 6
    Chang M H, Chen P J, Chen J Y, et al. Hepatitis B virus integration in hepatitis B virus-related hepatocellular carcinoma in childhood. Hepatology 1991; 13: 31620.
  • 7
    Chen D S, Sung J L. Maternal transmission of hepatitis B surface antigen in patients with hepatocellular carcinoma in Taiwan. Scand J Gastroenterol 1980; 15: 3214.
  • 8
    Tanaka H, Tukma H, Kasahara A, et al. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients. Int J Cancer 2000; 87: 7419.
  • 9
    Camma C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol 2001; 593602.
  • 10
    Jacobson L P, Zhang B C, Shu Y R, et al. Oltipratz chemoprevention trial in Qidong, People's Republic of China: study design and clinical outcomes. Cancer Edpidemiol Biomarkers Prev 1997; 6: 25765.
  • 11
    Egner P A, Wang J B, Shu Y R, et al. Chlorophyline intervention reduces aflatoxin–DNA adducts in individuals at high risk for liver cancer. Proc Natl Acad Sci 2001; 98: 146016.
  • 12
    Chuang S E, Kuo M L, Hsu C H, et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis 2000; 21: 3315.
  • 13
    Beasley R P, Hwang L Y, Lee G C Y, et al. Prevention of perinatally transmitted hepatitis B virus infection with hepatitis B immune globulin and hepatitis B vaccine. Lancet 1983; 2: 1099102.
  • 14
    Hsu S M, Chen D S, Chuang C H, et al. Efficacy of a mass hepatitis B vaccination program in Taiwan: studies on 3464 infants of hepatitis B surface antigen-carrier mothers. JAMA 1988; 260: 22315.
  • 15
    Chen D S, Hsu N H M, Sung J L, et al. A mass vaccination program in Taiwan against hepatitis B virus infection in infants of hepatitis B surface antigen-carrier mothers. JAMA 1987; 257: 2597603.
  • 16
    Poovorawan Y, Sanpavat S, Pongpunlert W, Chumdermpadetsuk S, Sentrakul P, Safary A. Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen-positive mothers. JAMA 1989; 261: 327881.
  • 17
    Hsu H Y, Chang M H, Chen D S, et al. Baseline seroepidemiology of hepatitis B virus infection in children in Taipei, 1984: a study just before mass hepatitis B vaccination program in Taiwan. J Med Virol 1986; 18: 3017.
  • 18
    Ni Y H, Chang M H, Huang L M, et al. Hepatitis B virus infection in children and adolescents in an hyperendemic area: 15 years after universal hepatitis B vaccination. Ann Intern Med 2001; 135: 796800.
  • 19
    Whittle H, Jaffar S, Wansbrough M, et al. Observational study of vaccine efficacy 14 years after trail of Hepatitis B vaccination in Gambian children. BMJ 2002; 325: 56973.
  • 20
    Da Villa G, Picciottoc L, Elia S, Peluso F, Montanaro F, Maisto T. Hepatitis B vaccination: universal vaccination of newborn babies and children at 12 years of age versus high risk groups: a comparison in the field. Vaccine 1995; 13: 12403.
  • 21
    Chang M H, Chen C J, Lai M S, Hsu H M, Wu T C, Kong M S, Liang D C, Shau W Y, Chen D S. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336: 18559.
  • 22
    Chang M H, Shau W Y, Chen C J, We T C, Kong M S, Liang D C, et al. The effect of universal hepatitis B vaccination on hepatocellular carcinoma rates in boys and girls. JAMA 2000; 284: 30402.
  • 23
    Halsey N A, Duclos P, Van Damme P, Margolis H.on behalf of the Viral hepatitis Prevention Board. Hepatitis B vaccine and central nervous system demyelinating diseases. Pediatr Infect Dis J 1999; 18: 234.
  • 24
    Pichichero M E, Cernichiari E, Lopreiato J, Treanor J. Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet 2002; 360: 173741.
  • 25
    Tang J R, Hsu H U, Lin H H, Ni Y H, Chang M H. Hepatitis B surface antigenemia at birth: a long-term follow-up study. J Pediatr 1998; 133: 3747.
  • 26
    Lin H H, Chang M H, Chen D S, et al. Early predictor of the efficacy of immunoprophylaxis against perinatal hepatitis B transmission: analysis of prophylaxis failure. Vaccine 1991; 9: 45760.
  • 27
    Chang M H, Hsu H Y, Huang L M, Lee P I, Lin H H, Lee C Y. The role of transplacental hepatitis B core antibody in the mother-to-infant transmission of hepatitis B virus. J Hepatol 1996; 24: 6749.
  • 28
    Kane M A. Global status of hepatitis B immunization. Lancet 1996; 348: 696.
  • 29
    Kane M. Hepatitis B control through immunization. In: RizzettoM, PurcellR H, GerinJ L, VermeG, eds. Viral Hepatitis and Liver Diseases. Turin: Edizioni Minerva Medica, 1997; 5766.
  • 30
    Kane M A, Brooks A. New immunization initiatives and progress toward the global control of hepatitis B. Curr Opin Infect Dis 2002; 15: 4659.